Home>Topics>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Gene therapy takes step forward as GSK files for EU approval

    Headlines

    Tue, 5 May 2015

    LONDON, May 5 (Reuters) - GlaxoSmithKline said on Tuesday it had submitted a gene therapy for approval in Europe, becoming the first big drugmaker to seek marketing authorisation for the technology to fix faulty genes.

  2. CORRECTED-U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug

    Headlines

    Fri, 1 May 2015

    April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said.

  3. Doubts grow over GlaxoSmithKline's $6 bln capital return plan

    Headlines

    Fri, 1 May 2015

    LONDON, May 1 (Reuters) - GlaxoSmithKline may ditch a plan to return 4 billion pounds ($6.1 billion) to investors, some analysts believe, as the drugmaker prepares to set out its vision for the...

  4. U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug

    Headlines

    Thu, 30 Apr 2015

    April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said.

  5. GSK shingles vaccine shows benefits across all age groups

    Headlines

    Tue, 28 Apr 2015

    LONDON, April 28 (Reuters) - An experimental shingles vaccine from GlaxoSmithKline is effective across all age groups, researchers said on Tuesday, boosting the prospects of a key product in the British drugmaker's development pipeline.

  6. GSK readies "bubble boy" drug as big pharma bets on gene therapy

    Headlines

    Mon, 27 Apr 2015

    LONDON, April 27 (Reuters) - GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes.

  7. World's first malaria vaccine moves closer to use in Africa

    Headlines

    Thu, 23 Apr 2015

    LONDON, April 24 (Reuters) - The world's first malaria vaccine, made by GlaxoSmithKline , could be approved by international regulators for use in Africa from October after final trial data showed it offered partial protection for up to four years.

  8. Novartis Posts Solid 1Q as the Divestiture of Lower-Margin Businesses Expands Margins

    Commentary

    Thu, 23 Apr 2015

    shifts (sales of the animal health and vaccine businesses and the creation of the consumer health joint venture with GlaxoSmithKline ). We expect this trend of minor top line growth to continue through current Diovan patent loss and the Gleevec patent

  9. BRIEF-ZappRx says raised $5.6 mln in funding

    Headlines

    Thu, 2 Apr 2015

    * ZappRx says raised a $5.6 million series a round led by sr one, the venture arm of Glaxosmithkline

  10. GSK Nigeria 2014 pretax falls 36 pct to 2.7 bln naira

    Headlines

    Thu, 2 Apr 2015

    LAGOS, April 2 (Reuters) - GlaxoSmithKline Consumer Nigeria said on Thursday it's 2014 pretax profit fell 36.2 percent to 2.75 billion naira ($14 million).

« Prev12345Next »
Content Partners